Omeros Corporation (LON:0KBU)

Market Cap	209.59M
Revenue (ttm)	n/a
Net Income (ttm)	-89.39M
Shares Out	n/a
EPS (ttm)	-1.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,174
Average Volume	2,782
Open	4.200
Previous Close	4.260
Day's Range	4.125 - 4.200
52-Week Range	2.950 - 13.589
Beta	n/a
RSI	50.82
Earnings Date	Aug 7, 2025

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-bind...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1994
• Employees: 202
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0KBU

Financial Performance

Financial numbers in USD